Company ASLAN Pharmaceuticals Limited

Equities

ASLN

US04522R2004

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per region

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-18 pm EDT			5-day change	1st Jan Change
0.54 ^USD	+9.98%		0.00%	+3.43%

Apr. 18	Asian Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading	MT
Apr. 17	Asian Equities Traded in the US as American Depositary Receipts Remain Flat in Wednesday Trading	MT

ASLAN Pharmaceuticals Limited is a clinical-stage immunology focused biopharmaceutical company. The Company's portfolio is led by eblasakimab (ASLAN004), a potential human monoclonal antibody that binds to the IL-13 receptor a1 subunit (IL-13Ra1), blocking signaling of two pro-inflammatory cytokines, IL-4 and IL-13, which are central to triggering symptoms of atopic dermatitis, such as redness and itching of the skin. It is conducting a Phase II b clinical trial investigating eblasakimab as a therapeutic antibody for moderate-to-severe atopic dermatitis (AD). The Company is also developing farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase (DHODH) that has the potential to be a therapy for autoimmune disease. The Company is also focused on developing antagonists of the aryl hydrocarbon receptor (AhR), an immune checkpoint inhibitor, through a joint venture.

Number of employees: 34

USD in Million	2022	Weight	2023	Weight	Delta
Cancer Novel Drugs 100.0 %	0	nan %	12	100.0 %	-

USD in Million	2022	Weight	2023	Weight	Delta
Japan 100.0 %	-	-	12	100.0 %	-

Managers	Title	Age	Since
Carl Aslan Jason Morton Firth FOU	Founder	51	09-12-31
Kiran Kumar Asarpota DFI	Director of Finance/CFO	45	10-10-31
Alexandre Kaoukhov CTO	Chief Tech/Sci/R&D Officer	-	22-03-14
Stephen Doyle PRN	Corporate Officer/Principal	50	18-01-31
Ben Goodger LAW	General Counsel	61	16-10-31

Members of the board	Title	Age	Since
Robert Hoffman BRD	Director/Board Member	58	18-10-29
Andrew James Howden CHM	Chairman	64	16-03-31
Carl Aslan Jason Morton Firth FOU	Founder	51	09-12-31
Kathleen Metters BRD	Director/Board Member	66	21-03-17
Neil Graham BRD	Director/Board Member	65	21-02-17

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	337,297,360	333,924,386 ( 99.00 %)	0	99.00 %

Name	Equities	%	Valuation
BVF, Inc. 4.715 %	1,049,999	4.715 %	645 749 $
UBS Group AG (13f Subfiler) 2.807 %	625,000	2.807 %	384 375 $
Citadel Securities GP LLC 2.169 %	482,963	2.169 %	297 022 $
Shay Capital LLC 1.796 %	400,000	1.796 %	246 000 $
Sio Capital Management LLC 1.141 %	254,150	1.141 %	156 302 $
Renaissance Technologies LLC 0.7760 %	172,801	0.7760 %	106 273 $
Parkman Healthcare Partners LLC 0.4969 %	110,658	0.4969 %	68 055 $
Landscape Capital Management LLC 0.3739 %	83,259	0.3739 %	51 204 $
Millennium Management LLC 0.3609 %	80,362	0.3609 %	49 423 $
Waterfront Wealth, Inc. 0.1838 %	40,941	0.1838 %	25 179 $

Name	Equities	%	Valuation
K2 Healthventures Equity Trust LLC 3.232 %	11,235,955	3.232 %	1 M $
Florian Schönharting 1.889 %	6,567,249	1.889 %	807 772 $
Carl Aslan Jason Morton Firth 1.006 %	3,495,836	1.006 %	429 988 $
The Lind Partners LLC 0.3596 %	1,250,000	0.3596 %	153 750 $
Andrew James Howden 0.3047 %	1,059,315	0.3047 %	130 296 $
Ben Goodger 0.0380 %	132,000	0.0380 %	16 236 $
Kiran Kumar Asarpota 0.0333 %	115,871	0.0333 %	14 252 $
Stephen Doyle 0.0178 %	61,980	0.0178 %	7 624 $
Tang Capital Management LLC 0.000001 %	5	0.000001 %	1 $
Alexandre Kaoukhov 0.000000 %	0	0.000000 %	- $

Aslan Pharmaceuticals Ltd.

3 Temasek Avenue 18 Level Centennial Tower

039190, Singapore

http://www.aslanpharma.com

address ASLAN Pharmaceuticals Limited(ASLN)

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.54 USD

Average target price

10 USD

Spread / Average Target

+1,751.85%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
ASLAN PHARMACEUTICALS LIMITED	+3.43%	11.11M
VERTEX PHARMACEUTICALS INCORPORATED	-3.30%	102B
REGENERON PHARMACEUTICALS, INC.	+1.79%	96.84B
ARGENX SE	-0.44%	21.48B
BIONTECH SE	-18.35%	20.82B
GENMAB A/S	-7.45%	18.6B
WUXI APPTEC CO., LTD.	-40.31%	16.81B
BEIGENE, LTD.	-26.84%	13.78B
NEUROCRINE BIOSCIENCES, INC.	+0.59%	13.4B
SAREPTA THERAPEUTICS, INC.	+20.86%	11.06B

Bio Therapeutic Drugs